CUI,STR
C1522449,Radiation Treatment
C0677850,Adjuvant therapy
C0001758,after treatment
C4289789,cfDNA
C4289789,Cell free DNA
C1521991,Molecular
C0206692,Infiltrating lobular carcinoma
C1134719,Infiltrating Ductal Carcinoma
C1516048,Assessed
C0338204,Herceptin
C0108779,CD3
C0039194,T-Cells
C0524469,Left shoulder
C0205358,Soft
C0225317,soft tissue
C0040300,tissue
C0040421,Palatine Tonsil
C0034001,Pterygoid muscle
C0279068,Solid Tumor
C0884358,Performed
C1549625,Ethnicity unknown
C0086528,Latino
C0239307,European
C0332196,Exclude
C1417836,NOT
C0037750,Spanish
C3639994,Discordance
C1707513,Copy Number
C0021044,IHC
C0002808,Anatomy
C0027627,Metastasis
C0807712,Recurrence date
C4744823,Metastatic Sample
C1953343,Chromosome number
C0015250,Complete Resection
C0205145,Site
C1515974,Anatomic Location
C0006802,CM
C0475210,centimeter
C0205390,Stage
C1521733,Pathologic
C0030664,Pathological
C1521801,Administered
C0445204,Pre-operative
C0600558,Neoadjuvant Therapy
C0205090,Right
C0004454,Axilla
C0038894,Surgery
C0205091,Left
C0011900,Diagnosis
C1373200,Order
C0439064,Multiple
C0282416,Overall
C1522508,Detailed
C0205435,1st
C0205435,First
C0332307,Type
C0011008,Date
C0205276,Local
C0699885,BLADDER CARCINOMA
C0005682,Bladder
C0132555,NOS
C0007097,Carcinoma
C0205281,Invasive
C0370003,Sample
C0439165,Percent
C0439810,Total
C1265611,Quantity
C0237753,Number
C0750480,Count
C0439673,Unknown
C0027361,Person
C1517741,Last
C0017428,Genomic
C0002778,Analysis
C0017296,GENETIC
C0030705,Patient
C0035168,research
C0004793,Sequence
C0282411,Comment
C0242939,adjuvant radiotherapy
C0034619,radiotherapy
C1515974,Anatomic Site
C0021044,Immunohistochemistry
C0034833,Progesterone Receptor
C0034804,estrogen receptor
C1335475,Primary Carcinoma
C1708790,Lymphovascular Invasion
C0439743,Multicentric
C0746319,Positive Lymph Node
C0025663,Method
C0589120,follow up
C0205462,Histological
C0449560,Subtype
C0026882,Mutation
C3271329,DMP
C0600091,Identifier
C0231220,Symptomatic
C0026985,Myelodysplasia
C1306459,primary cancer
C2090600,signed:
C1513491,Most Recent
C1257909,Somatic
C0428772,LVEF
C0178932,quality assurance
C0447660,Quadrant of breast
C0332306,Quality
C0034786,Androgen Receptor
C1519814,Update
C3827420,Incorrect
C1511481,Consent
C4519079,veledimex
C0205250,High
C1517033,Definitive Radiation Therapy
C0149741,nipple discharge
C0028109,Nipple
C0001575,Uterine adnexa
C0001575,adnexa
C1518340,No Evidence of Disease
C0086409,Hispanic
C0240318,Mediastinal mass
C0205448,Two
C0205447,One
C0227048,13
C0034043,Puerto Rican
C0013014,Dominican Republic
C3840603,Spanish Surname only
C1553379,Cuban
C0185115,Extraction
C4053573,LY3023414
C4287738,LY3022855
C3273551,LY2835219
C4511913,CEDM
C0024485,MRI
C0282411,Comment
C0808070,Start Date
C0080194,Strain
C0677922,ovarian suppression
C0450429,Location
C0005525,Immunotherapy
C0279025,Endocrine therapy
C0013216,Chemotherapy
C0475373,T2
C2698020,Mass Density
C0006660,Calcification
C1659543,Breast Density
C2347029,Sample Type
C0205547,Routine
C0424860,Size of mass
C3166257,Reason stopped
C4738935,Collection setting
C1827571,Depth of lesion
C0447660,Breast quadrant
C0392360,indication
C0009488,comorbidities
C0015031,Ethnicity
C2598519,Current age
C0034519,Radiation
C0242596,MRD
C0036525,metastatic
C0001551,Adjuvant
C1882413,PARP Inhibitors
C1511314,BIRADS
C0023114,laterality
C0449523,Type of scan
C0030664,Pathology
C1519386,Smoking Status
C0015663,Fast
C0009458,Medium
C0439834,Slow
C2964353,Plateau
C0205322,Persistent
C0205387,Clumped
C0205219,Diffuse
C0205147,regional
C1668248,Iso
C0424295,Hyper
C3660928,GDC0032
C4330917,GDC0077
C0080194,Strain
C0522501,Marked
C0547040,Minimal
C0205099,Central
C0205122,Segmental
C0205132,Linear
C1308727,RIM
C4698330,Homogenous
C0522501,Marked
C0547040,Minimal
C0439742,Scattered
C0015252,resection
C0439742,Scattered
C0205234,Focus
C0241165,SKIN THICKENING
C3476657,Troubleshooting
C4331246,Restaging
C0332305,Staging
C0450363,3D
C1442455,2D
C0205314,New
C0442808,Increasing
C0205360,Stable
C4727091,Obscured
C0015677,Fat
C0205251,low
C0205163,Equal
C4684449,On Treatment
C2709088,post treatment
C2709094,pre treatment
C4331277,Seviteronel
C1565489,Renal impairment
C0257685,zoledronic acid
C3711165,VS5584
C0078257,vinorelbine
C0042679,Vincristine
C0042670,Vinblastine
C1958300,veliparib
C2986853,TRX518
C3887576,Lucitanib
C2351038,tremelimumab
C0728747,trastuzumab
C0076836,Toremifene
C1872681,tesetaxel
C1707080,temsirolimus
C0076080,temozolomide
C4287740,LSZ102
C0039286,Tamoxifen
C1831828,TALIMOGENE LAHERPAREPVEC
C3827166,Pegilodecakin
C4519167,Tucatinib
C4055433,atezolizumab
C3492270,ricolinostat
C4519079,veledimex
C1564985,Abraxane
C0675974,tanespimycin
C4524315,larotrectinib
C0279284,Doxil
C0232970,Postmenopausal
C0205271,Irregular
C2348042,Parallel
C0205394,Other
C0728938,Partial
C0205101,Outside
C1513120,MSKCC
C0016360,Fluorouracil
C4329338,FAZ053
C0851344,exemestane
C2986399,BYL719
C4053677,AZD1775
C0290883,anastrozole
C0338204,Herceptin
C1516119,sorafenib
C3827076,SGN-LIV1A
C1609861,Seliciclib
C0764827,sapacitabine
C4086837,sacituzumab govitecan
C4527407,LOXO195
C2931926,ruxolitinib
C4045494,ribociclib
C4330586,RGX-104
C4310558,PUH71
C4310558,PU-H71
C2984037,PTC299
C0032042,placebo
C1328025,pertuzumab
C3658706,pembrolizumab
C4053607,PDR001
C3853822,palbociclib
C0144576,Paclitaxel
C0069717,oxaliplatin
C2316164,olaparib
C3657270,nivolumab
C3896705,NeuVax
C3640300,LJM716
C2713008,neratinib
C2933427,MK2206
C0026259,Mitoxantrone
C0279565,Invasive Lobular Carcinoma
C0027667,Unknown primary cancer
C0729594,Axillary lymph nodes
C0037925,Spinal Cord
C0035359,Retroperitoneum
C0003962,Ascites
C0926578,Right orbit
C1281868,Hilar lymph node
C0016366,Fluoxymesterone
C4055109,durvalumab
C4042960,talazoparib
C0278488,metastatic breast cancer
C0541315,everolimus
C0015133,Etoposide
C1723386,ertumaxomab
C0935916,fulvestrant
C2350866,eribulin
C0246415,docetaxel
C3899465,DLYE5953A
C1690432,denosumab
C1511767,Dendritic Cell Vaccine
C3827127,debio 1347
C0014582,Epirubicin
C3496793,enzalutamide
C0010583,Cyclophosphamide
C1176309,bortezomib
C2987384,BMN673
C3491291,BKM120
C2981819,BGJ398
C0796392,bevacizumab
C4049146,Cobimetinib
C4053676,AZD9496
C1831929,CNF2024
C0008838,Cisplatin
C0007257,Carmustine
C0079083,Carboplatin
C0671970,capecitabine
C3181682,cabozantinib
C0205250,High
C0444686,calc
C0332514,Asymmetry
C0439745,Grouped
C2662648,Amorphus
C0038894,Surgery
C1318309,Core Biopsy
C0024671,Mammogram
C0024299,Lymphoma
C1266089,Metaplastic carcinoma
C1449563,IDC
C0007124,DCIS
C0238767,Bilateral
C0439743,Multicentric
C0205292,Multifocal
C0332221,Satellite
C0037179,Single
C0034510,Race
C0441833,Panel
C0132555,NOS
C0205081,Moderate
C1513302,MILD
C0205234,Focal
C1549495,Never
C0205156,Former
C0006142,Breast Cancer
C1831920,ABT888
C3852841,abemaciclib
C0279680,Bladder Urothelial Carcinoma
C1336860,Undifferentiated Malignant Neoplasm
C0007117,Basal cell carcinoma
C0221013,Systemic mastocytosis
C0278701,stomach adenocarcinoma
C1336027,Solid Papillary Carcinoma of the Breast
C1261473,Sarcoma NOS
C0279702,renal clear cell carcinoma
C0149978,Rectal adenocarcinoma
C0281361,Pancreatic adenocarcinoma
C0010606,Adenoid Cystic Carcinoma
C0007131,non small cell lung cancer
C0027022,Myeloproliferative neoplasm
C0026985,Myelodysplasia
C1275874,Metaplastic squamous cell carcinoma
C0025202,melanoma
C1265996,Large cell neuroendocrine carcinoma
C0019621,langerhans cell histiocytosis
C0853879,Invasive breast carcinoma
C0017636,Glioblastoma multiforme
C0024301,follicular lymphoma
C0001418,ADENOCARCINOMA NOS
C0338106,COLON ADENOCARCINOMA
C0206698,Cholangiocarcinoma
C0027641,Breast neoplasm NOS
C0023467,Acute myeloid leukemia
C0678222,Breast Carcinoma
C0040128,Thyroid
C0034882,Rectum
C0030274,Pancreas
C0700374,Palate
C0004600,Back
C0238729,Axillary mass
C0042567,Vertebrate
C0042150,uterus cervix
C0042131,uterus
C0040578,Trachea
C0038351,Stomach
C0038293,Sternum
C0037993,Spleen
C0037949,Spine
C0225317,soft tissue
C0021852,Small bowel
C0178298,Skin
C0036277,Scapula
C0036270,Scalp
C4047398,Sacral mass
C0035561,Rib
C0004454,Axilla
C0035359,Retroperitoneum
C0225778,Pleural fluid
C0032225,Pleura
C0031153,Peritoneum
C0003964,Peritoneal Fluid
C0031050,Pericardium
C0030797,Pelvis
C0029928,Ovary
C0230060,Orbital floor
C0029180,Orbit
C0028977,Omentum
C0686905,Not Available
C1272460,Not Applicable
C0027530,Neck
C0026845,Muscle
C0025066,Mediastinum
C0003617,Appendix
C0240318,Mediastinal mass
C0024204,Lymph node
C0024109,Lung
C0023884,Liver
C0022646,Kidney
C0230136,Intercostal space
C0020889,Iliac bone
C0018787,Heart
C0001625,Adrenal gland
C0018246,Groin
C0016976,Gallbladder
C0015811,Femur
C0015556,fallopian tube
C0014852,Esophagus
C0228134,epidural
C0009368,Colon
C0205076,Chest Wall
C0007874,Cervix
C0007765,Cerebellum
C0006497,Buttock
C0006141,Breast
C0006104,Brain
C0021853,Bowel
C0005953,Bone Marrow
C0262950,Bone
C0005682,Bladder
C0836916,Abdominal Wall
C0025677,Methotrexate
C0065879,Megestrol Acetate
C4527228,LY3321367
C0278925,Chemoprevention
C0600558,Neoadjuvant
C0020823,Ifosfamide
C4287757,GWN323
C0120107,Goserelin
C0079460,GMCSF
C2827489,Glembatumumab
C0085272,Leuprolide
C0023413,Leucovorin
C0246421,letrozole
C2986924,lenvatinib
C1506770,lapatinib
C1831723,Gerson Therapy
C4053626,LAG525
C1135132,ixabepilone
C0123931,irinotecan
C1367202,ipilimumab
C4287754,INCAGN01876
C0045093,gemcitabine
C0376409,Patient Preference
C0549178,ONGOING
C0040539,toxicity
C0242656,Disease Progression
C1518340,NED
C2984520,GDC0980
C2606671,GDC0941
C0011900,Diagnostic
C0199230,screening
C0332490,Round
C1709367,Oval
C4700163,Not parallel
C0205143,Angular
C1282914,Circumscribed
C4697722,Hyperechoic
C0439855,Complex
C0231242,Complicated
C0205352,Simple
C0205217,Increased
C0332197,Absent
C0577559,Mass
C0919479,Yes
C0028128,NO
C0241165,SKIN THICKENING
C0221370,NIPPLE RETRACTION
C4227447,Skin retraction
C0205090,Right
C0205091,Left
C0521116,Current
C0007457,White
C0439673,Unknown
C0205394,Other
C0282204,Native American
C0085756,Black or African American
C0919479,Yes
C0028128,NO
C0686905,Not Available
C0013089,Doxorubicin
C0018801,Heart failure
C0002965,Unstable angina
C0027051,Myocardial Infarction
C0031039,Pericardial effusion
C0806020,End date
C0020792,Identification
C1710360,Platform
C1517586,Investigational
C0439792,Extent
C0205307,Unremarkable
C3827727,Undetectable
C0370003,Specimen
C1302584,Date of report
C0887950,Genomics
C4289789,Cell free DNA
C0028580,Magnetic Resonance
C0037088,Clinical finding
C1547538,Facility
C1510755,Accession
C1269792,Surgical pathology number
C1300638,Identification number
C0220784,anatomic
C0030664,Pathology
C0007124,Ductal Carcinoma In Situ
C0332514,Asymmetry
C0205284,Margin
C0577559,Mass
C0405352,breast biopsy
C0441915,AJCC
C0442310,Clockface position
C1413503,CLOCK
C1317250,Collection Date
C1511314,BI-RADS
C0449774,Pattern
C1627358,Enhancement
C0024204,Lymph node
C0221198,Lesion
C1152568,CDK inhibitor
C0246957,CDK4
C1506770,lapatinib
C4505403,Emtansine
C0441471,Event
C0007226,Cardiovascular
C1320716,Cardiovascular event
C0949266,experimental therapy
C2985566,Targeted Therapy
C0019994,Hospital
C0017446,geographic location
C0450429,Location
C0080264,ultrasound of breast
C0006142,Breast Cancer
C0085272,Leuprolide
C0120107,Goserelin
C0311392,physical finding
C0743997,Incidental Finding
C0444507,Incidental
C0028794,Occult
C0344104,Magnetic resonance imaging of breast
C1513126,Menopausal Status
C0411881,Diagnostic mammogram
C0203028,screening mammogram
C2348558,Study Date
C0011923,Imaging
C0184661,Procedure
C1511314,BIRAD
C1292734,Treatment intent
C0162425,intent
C1276305,Curative
C0392360,indication
C0441833,Panel
C0024204,lymph nodes
C0476270,Cardiovascular symptom
C1881055,History of Coronary Artery Disease
C0034619,radiation therapy
C0337950,Treatment site
C1510755,Accession Number
C0807321,Histology Report
C4050242,Pathologic Complete Response
C0443276,Pathological staging
C0205563,Clinical staging
C0205563,Clinical stage
C1512706,Cancer History
C0006144,Breast Cyst
C0746405,cystic mass
C0040405,CT scan
C0024485,Magnetic Resonance Imaging
C1517586,Experimental
C0920425,cancer treatment
C0039798,treatment
C4068833,Vascularity
C0344441,Histology NOS
C1134719,Invasive Ductal Carcinoma
C0279754,ER Positive
C0279756,ER Negative
C0009488,Comorbidity
C0027646,Cancer stage
C0279756,Estrogen receptor negative
C0279754,Estrogen receptor positive
C0445085,NX
C0441961,N3
C4684527,Supraclavicular Fossa
C0009488,comorbidities
C0041618,Ultrasound
C1301894,Medical record number
C0456389,size
C0205292,Multifocal
C0019638,Histology
C0456201,Histological grade
C1518435,Nuclear Grade
C1516974,Estrogen Receptor Status
C1514471,Progesterone Receptor Status
C0027365,Name
C0421451,Date of birth
C0001779,Age
C0079399,Gender
C0034510,Race
C0015031,Ethnicity
C0678222,Breast Carcinoma
C0449438,Status
C0007124,DCIS
C2316983,Date of diagnosis
C0205225,Primary
C0006826,Cancer Type
C1146895,Vital status
C1522577,Followup
C1148348,Death Date
C1334274,Invasive Carcinoma
C0279025,Endocrine therapy
C0005525,Immunotherapy
C0872338,cancer site
C1659543,Breast Density
C1823256,TCHP
C0728747,trastuzumab
C2935436,Trastuzumab emtansine
C1268567,Tyrosine Kinase Inhibitor
C2698020,Mass Density
C0006660,Calcification
C0729594,Axillary lymph node
C1511314,BIRADS
C0023114,laterality
C0447660,Breast quadrant
C1519386,Smoking Status
C0488055,Systolic blood pressure
C0004057,Aspirin
C0360714,statin
C0001645,Beta Blocker
C0003015,ACE inhibitor
C1561643,Chronic Kidney Disease
C0017654,Glomerular Filtration Rate
C0428772,Left ventricular ejection fraction
C0034519,Radiation
C4289789,cfDNA
C1882413,PARP inhibitor
C0677922,ovarian suppression
C2975395,navitoclax
C3492270,ricolinostat
C0021764,Interleukin
C0016366,Fluoxymesterone
C0720810,Halotestin
C4524315,larotrectinib
C4726721,Sacituzumab
C0205699,Carcinomatosis
C0014852,Esophagus
C1947913,LOCOREGIONAL
C0332221,Satellite
C0024671,Mammogram
C0439855,Complex
C4697722,Hyperechoic
C0003811,Arrhythmia
C0038454,Stroke
C0011847,Diabetes
C0020538,Hypertension
C0020473,Hyperlipidemia
C0031046,Pericarditis
C0687676,Post
C1513853,NON
C0006141,Breast
C1517886,Early Stage
C0006826,Cancer
C0027651,Neoplasm
C0205179,Advanced
C0036525,metastatic
C1519810,Unresectable
C0034897,Recurrence
C0205174,Triple
C3845275,Germline
C0439677,Myeloid
C0023418,leukemia
C0007140,Carcinosarcoma
C0001418,Adenocarcinoma
C0475468,Esophagogastric
C0038351,Gastric
C0439682,Follicular
C0017636,Glioblastoma multiforme
C0205082,High grade
C0440743,Serous
C0019618,Histiocytosis
C0549177,Large
C0027912,Neuroendocrine
C0007095,Carcinoid
C1182670,Squamous
C1709160,Neoplastic
C0205332,Reactive
C0700321,Small
C0030274,Pancreatic
C0007589,Differentiated
C0205052,rectal
C0022646,Renal
C1261473,Sarcoma
C0024899,Mastocytosis
C0205112,Basal
C0521164,Ring
C0000726,Abdominal
C0015811,Femur
C0086590,Marrow
C0007103,Endometrium
C0205150,Hilar
C0020889,Iliac
C0230136,Intercostal space
C0441989,Ipsilateral
C0025066,Mediastinal
C0699036,Orbital
C0442146,Parasternal
C0031153,Peritoneal
C0036037,Sacral
C0037004,Shoulder
C0262950,Bone
C0024202,Lymph
C0243045,CDK
C0072108,Cyclin
C0429964,dependent
C0031727,Kinase
C0038951,4
C0152407,6
C1540292,PDL1
C0007587,Cell Death
C0023688,ligand
C0205447,1
C1999216,Inhibitor
C1958300,veliparib
C0045246,abt
C0041271,Salpingectomy
C0054252,BSO
C0238767,Bilateral
C0587605,Palliative
C0589496,Supraclavicular
C0325079,Fossa
C1514164,Pleomorphic
C1513269,Microcyst
C1326330,septation
C1269955,Invasion
C0030747,pectoralis
C0009924,Contrast
C0444669,Core
C0005558,Biopsy
C0010054,coronary artery disease
C0027061,Myocardial
C0021308,Infarction
C0205100,Peripheral
C0005847,Vascular
C0741847,Bypass
C0184661,Intervention
C0018787,Heart
C0231174,Failure
C0184252,VALVE
C0000768,ABNORMALITY
C0035139,Replacement
C0031050,Pericardial
C0013687,effusion
C0443343,Unstable
C0002962,Angina
C0003811,Arrythmia
C0001551,Adjuvant
C0014136,Endocrine
C0003241,Antibody
C0242656,Progression
C1547580,Preop
C0205211,Subclinical
C0034599,Radiology
C0221198,Lesions
C4042960,talazoparib
C0011305,Dendritic
C4055109,durvalumab
C0108779,CD3
C0069515,neu
C4519167,Tucatinib
C4055433,atezolizumab
C0675974,tanespimycin
C1538577,PARP
C0137710,polyadenosine
C0034320,diphosphate
C0035549,Ribose
C1335439,Polymerase
C0006141,Mammary
C0231290,After
C0013216,Chemotherapy
C0600558,Neoadjuvant
C0205160,Negative
C1446409,Positive
C0069515,HER2
C0037750,Spanish
C1268647,Extremely dense
C0034802,EGFR
C1512426,Heterogenous
C0205462,Histologic
C0021756,interleukin 2
C4264446,Mixed carcinoma
C4042790,Quad
C1521726,partial response
C0677874,Complete Response
C3843777,Currently taking
C3258293,Valvular disease
C1710661,Washout
C0086409,Hispanic origin
C0015031,Ethnic Origin
C0079946,origin
C0034510,Racial group
C1532697,Unknown racial group
C0425355,European origin
C0086409,Spanish Origin
C0456984,test results
C0005507,Assay
C0206492,bispecific antibody
C0007465,Cause of Death
C0011065,Death
C4036190,"Yes, another Hispanic, Latino-a, or Spanish origin"
C0456984,Test Result
C0025474,Mesentery
C3869435,Genomic Sequencing Procedures and Other Molecular Multianalyte Assays
C0027651,Tumor
C4322612,Parasternal part of chest
C0205095,Posterior
C2926098,Death due to CV causes
C0741923,cardiac event
C4552344,Acute cardiac event
C0205082,Severe
C1299222,Sample identification number
C3176918,Clinical setting
C0600644,Collection
C0200345,sample collection
C0231290,Status post
C0332155,untreated
C0741886,cancer resection
C4743572,Definitive Surgical Resection
C0332152,Before
C0206492,bispecific antibody
C0449695,Primary site
C0243140,histopathology
C0807944,Site of distant metastasis
C0039593,Testing
C0022885,Test
C0242596,minimal residual disease
C0334699,Myoepithelial carcinoma
C0678222,Breast carcinoma NOS
C1513792,Myeloproliferation
C0206696,Signet ring cell carcinoma
C0302523,Observation
C2212591,signet ring cell carcinoma of bladder
C1512742,"Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant"
C0030669,surgical pathology
C1710255,Surgical Pathology Report
C3865711,Solid organ neoplasm genomic sequence analysis panel with DNA analysis
C3899030,Germline Genotype Analysis
C1285573,Genotype Analysis
C0002778,Analysis
C3708687,Gene analysis for detection of somatic variant
C0027643,Local Neoplasm Recurrence
C0746922,Node
C1319030,Marker lymph node status unknown
C0746919,NO TREATMENT
C0597357,receptor
C0807321,Pathology report
C0079722,tumor infiltrating lymphocyte
C0877341,Coronary revascularization
C1275833,Partial response to treatment
C0456201,Histological grade
C4050242,Pathologic Complete Response
C0205563,Clinical stage
C1268997,Upper gastrointestinal tract
C3273724,adenovirus-mediated human interleukin-12 INXN-2001 plus veledimex
C2981832,Anti-CD3 x Anti-Her2/neu Bispecific Antibody-Armed Activated T Cells
C0853879,Breast cancer invasive NOS
C0521941,Antiresorptive Agents
C3846095,Not done/Not applicable
C0205250,High
C1317250,Collection Date
C1517033,Definitive Radiation Therapy
C0425812,Nipple discharge present (situation)
C1518340,No Evidence of Disease
C0199975,Interleukin-2 therapy
C0347918,Radiology equipment type NOS
C1334708,Metaplastic carcinoma of breast
C1334807,Invasive Mucinous Breast Carcinoma
C0230267,Entire paracolic gutter (body structure)
C0334355,"Serous cystadenoma, borderline malignancy"
C1513365,Mixed Epithelial/Mesenchymal Metaplastic Breast Carcinoma
C0749424,"Thyroid cancer, Hurthle cell"
C3642254,High Grade Ovarian Serous Adenocarcinoma
C1332166,Adenocarcinoma of the Esophagogastric Junction
C0010606,Adenoid Cystic Carcinoma
C4722301,Trastuzumab-Ixabepilone
C4477758,letrozole-ribociclib
C4688493,letrozole-palbociclib
C4522219,Bevacizumab-Paclitaxel
C1880379,Docetaxel-Carboplatin
C4522213,Carboplatin-Gemcitabine
C0039871,Thiotepa
C0441988,Contralateral
C0003962,Ascites
C0007140,Carcinosarcoma
C1334274,Invasive Carcinoma
C1621425,cribriform
C0334384,Ductal and Lobular Carcinoma
C0035359,Retroperitoneum
C0926578,Right orbit
C0441989,Ipsilateral
C1281868,Hilar lymph node
C0729594,Axillary lymph nodes
C0741899,Poorly differentiated carcinoma
C0334384,Ductal and Lobular Carcinoma
C0279565,Invasive Lobular Carcinoma
C1134719,Invasive Ductal Carcinoma
C0206696,Signet ring carcinoma
C0027667,Unknown primary cancer
C0014852,Esophagus
C0450366,3c
C0450365,3b
C0450354,2b
C0450353,2a
C3539878,Triple Negative Breast Cancer
C3844644,South or Central American
C3242233,patient refuse
C0282204,Native American
C0078988,Asian
C0919414,Zero
C1565489,Renal impairment
C1285155,Procedure by intent
C0013216,Chemotherapy
C0279025,Endocrine therapy
C2585119,Experimental therapeutic procedure
C0005525,Immunotherapy
C1882413,PARP Inhibitors
C0677922,ovarian suppression
C0439673,Unknown
C0450429,Location
C0808070,Start Date
C1656582,Date radiation ended:TmStp:Pt:Cancer.XXX:Qn
C3166257,Reason stopped
C0282411,Comment
C0006660,Calcification
C4331277,Seviteronel
C1417490,MUC1
C3896823,LOXO-101
C3827166,AM0010
C0717726,Liposomal Doxorubicin
C0016366,Fluoxymesterone
C3492270,Ricolinostat
C1831992,ABT263
C1564985,Abraxane
C1882413,PARP inhibitor
C0675974,17AAG
C4055433,Atezolizumab
C4519167,Tucatinib
C4055109,Durvalumab
C2987384,BMN673
C1561643,CKD
C1269792,Surgical Pathology Number
C0006802,cm
C2584899,date of procedure
C0205394,Other
C0242656,Progression
C0242596,Minimal Residual Disease
C0010054,coronary artery disease
C0205394,Other
C0439673,Unknown
C0205394,Other
C0587605,Palliative
C0205394,Other
C0195509,Bilateral salpingectomy
C2607234,STA9090
C0037949,Spine
C0262950,Bone
C1521902,specify
C1521902,specify
C0861352,LN
C0013313,Dura
C0031153,Peritoneum
C0205312,Papillary
C0205076,Chest wall
C1272460,N/A
C0439070,III
C0021968,I
C0020717,II
C0205616,Moderately Differentiated
C0205615,Well Differentiated
C0441959,N0
C1272460,Not Applicable
C0205179,Advanced
C1518340,NED
C1518340,NED
C0240339,Mexican
C0439673,Unknown
C0376409,Patient Preference
C0549178,Ongoing
C0040539,Toxicity
C0242656,Disease Progression
C0728938,Partial
C0205101,Outside
C1513120,MSKCC
C0257685,Zoledronic Acid
C3711165,VS5584
C0078257,Vinorelbine
C0042670,Vinblastine
C0042679,Vincristine
C1958300,Veliparib
C2986853,TRX518
C2351038,Tremelimumab
C0728747,Trastuzumab
C0076836,Toremifene
C1872681,TESEtaxel
C1707080,Temsirolimus
C0076080,Temozolomide
C0039286,Tamoxifen
C1831828,Talimogene Laherparepvec
C4042960,Talazoparib
C1516119,Sorafenib
C3827076,SGN-LIV1A
C1609861,Seliciclib
C0764827,Sapacitabine
C4086837,Sacituzumab govitecan
C2931926,Ruxolitinib
C4045494,Ribociclib
C4330586,RGX-104
C4310558,PUH71
C4310558,PU-H71
C2984037,PTC299
C0032042,Placebo
C1328025,PERTUZumab
C3658706,Pembrolizumab
C4053607,PDR001
C3853822,PALBOciclib
C0144576,Paclitaxel
C0069717,Oxaliplatin
C2316164,Olaparib
C3657270,Nivolumab
C3896705,Neuvax
C2713008,NERATinib
C2933427,MK2206
C0026259,Mitoxantrone
C0065879,Megestrol Acetate
C0025677,Methotrexate
C4527228,LY3321367
C4053573,LY3023414
C4287738,LY3022855
C3273551,LY2835219
C3887576,Lucitanib
C4287740,LSZ102
C4527407,LOXO195
C3640300,LJM716
C0290883,Anastrozole
C4330917,GDC0077
C3660928,GDC0032
C2984520,GDC0980
C2606671,GDC0941
C0935916,Fulvestrant
C4329338,FAZ053
C0016360,Fluorouracil
C0851344,Exemestane
C0541315,EVERolimus
C0015133,Etoposide
C1723386,Ertumaxomab
C2350866,Eribulin
C0085272,Leuprolide
C0246421,Letrozole
C0023413,Leucovorin
C2986924,Lenvatinib
C1506770,Lapatinib
C4053626,LAG525
C1135132,Ixabepilone
C0123931,Irinotecan
C1367202,IPILIMUmab
C4287754,INCAGN01876
C0020823,Ifosfamide
C4287757,GWN323
C0120107,Goserelin
C0079460,GMCSF
C2827489,Glembatumumab
C1831723,Gerson Therapy
C0045093,Gemcitabine
C1831920,ABT888
C3852841,ABEMAciclib
C3496793,Enzalutamide
C0014582,Epirubicin
C0013089,Doxorubicin
C0246415,Docetaxel
C3899465,DLYE5953A
C1690432,Denosumab
C1511767,Dendritic Cell Vaccine
C3827127,Debio 1347
C0010583,Cyclophosphamide
C4049146,Cobimetinib
C1831929,CNF2024
C0132555,NOS
C0008838,Cisplatin
C0079083,Carboplatin
C0007257,Carmustine
C0671970,Capecitabine
C3181682,CABOZANTInib
C2986399,BYL719
C1176309,Bortezomib
C2987384,BMN673
C3491291,BKM120
C2981819,BGJ398
C0796392,Bevacizumab
C4053676,AZD9496
C4053677,AZD1775
C0205394,other
C0227052,15
C0227051,14
C0227048,13
C0205458,12
C0205457,11
C0152401,10
C0205455,9
C0205454,8
C0205453,7
C0152407,6
C0038951,4
C0040999,5
C0205449,3
C0205448,2
C0205447,1
C0456148,None
C0278925,Chemoprevention
C0600558,Neoadjuvant
C0036525,Metastatic
C0242596,MRD
C0034519,Radiation
C0001551,Adjuvant
C0009488,Comorbidities
C0080194,Strain
C2199689,LV diastolic dimension
C0428772,LVEF
C0360714,Statin
C0001645,Beta-Blocker
C0488055,Systolic blood pressure
C0004057,Aspirin
C1519386,Smoking Status
C2347029,Sample Type
C0030664,Pathology
C0475373,T2
C1511314,BIRADS
C0006660,Calcification
C2698020,Mass density
C1827571,Depth of Lesion
C0447660,Breast Quadrant
C0023114,Laterality
C1659543,Breast Density
C0449523,Type of Scan
C1510755,Accession Number
C0392360,Indication
C0806020,End Date
C0808070,Start Date
C0337950,Treatment Site
C0162425,Intent
C0282411,Comment
C0450429,Location
C0205394,Other
C0677922,Ovarian Suppression
C1882413,PARP Inhibitors
C0005525,Immunotherapy
C0279025,Endocrine Therapy
C0013216,Chemotherapy
C0441833,Panel
C1518435,Nuclear Grade
C0019638,Histology
C0025646,M
C0031995,pN
C0030705,pT
C0009244,cT
C0008115,cN
C0006802,cM
C0441987,Side
C1148348,Death Date
C1146895,Vital Status
C0040300,Tissue
C0034510,Race
C0015031,Ethnicity
C0079399,Gender
C2598519,Current Age
C0301362,DOB
C0027365,Name
C1717139,MRN
C0348000,Instrument
C4289789,cfDNA
C0039798,Treatment
C0034619,Radiation Therapy
C0370003,Sample
C0027627,Metastasis
C0205225,Primary
C0011298,Demographics
C0185115,Extraction
C0018801,Heart Failure
C0031046,Pericarditis
C0031039,Pericardial Effusions
C0027051,Myocardial Infarction
C0002965,Unstable Angina
C0020538,hypertension
C0020473,hyperlipidemia
C0011847,diabetes
C0038454,stroke
C0003811,arrhythmia
C0018801,heart failure
C0028128,no
C0919479,yes
C1549495,Never
C0205156,Former
C0521116,Current
C1318309,Core Biopsy
C0038894,Surgery
C0024299,Lymphoma
C1266089,Metaplastic Carcinoma
C1366566,ILC
C1449563,IDC
C0007124,DCIS
C0522501,MARKED
C0547040,MINIMAL
C0205387,Clumped
C4698330,Homogenous
C0205219,Diffuse
C0205147,Regional
C0205122,Segmental
C0205132,Linear
C0205234,Focal
C1308727,Rim
C0439742,Scattered
C0522501,Marked
C0205081,Moderate
C1513302,Mild
C0547040,Minimal
C0205099,Central
C0205090,Right
C0205091,Left
C0241165,skin thickening
C0221370,Nipple retraction
C4227447,Skin retraction
C0028128,No
C2964353,Plateau
C0205322,Persistent
C0015663,Fast
C0439834,Slow
C0009458,Medium
C1272460,N/A
C0205314,New
C0442808,Increasing
C0205360,Stable
C1282914,Circumscribed
C0332490,Round
C1709367,Oval
C0424295,Hyper
C1668248,Iso
C0205234,Focus
C0577559,Mass
C3476657,Troubleshooting
C4331246,Restaging
C0332305,Staging
C0199230,Screening
C0919479,Yes
C0205217,Increased
C0332197,Absent
C0241165,Skin Thickening
C4697722,Hyperechoic
C0439855,Complex
C0205143,angular
C4700163,Not parallel
C0011900,Diagnostic
C0439745,Grouped
C2662648,Amorphus
C0205251,Low
C0015677,Fat
C0205163,Equal
C0205250,High
C4727091,Obscured
C0444686,Calc
C0332514,Asymmetry
C0450363,3D
C1442455,2D
C4511913,CEDM
C0024485,MRI
C0041618,US
C0024671,Mammogram
C0238767,Bilateral
C0439743,Multicentric
C0205292,Multifocal
C0332221,Satellite
C0037179,Single
C0030193,Pain
C1412365,Palp
C0205547,Routine
C1272460,Not applicable
C0037949,Spine
C0262950,Bone
C0006104,Brain
C0205076,Chest wall
C0542554,Internal mammary nodes
C4684527,Supraclavicular fossa
C0006141,Breast
C0004454,Axilla
C1420279,MSK
C0587605,Palliative
C1276305,Curative
C1547325,Pending
C4727545,IPILIMUmab-Nivolumab
C3827127,Debio1347
C3641122,MEDI4736
C0285590,Bicalutamide
C3502775,AZD5363
C4744692,Anastrozole-Lapatinib
C4744732,Letrozole-Trastuzumab
C4722211,Fulvestrant-Trastuzumab
C4722261,Tamoxifen-Trastuzumab
C4522240,Carboplatin-Paclitaxel-Trastuzumab
C4744775,Carboplatin-Trastuzumab
C4521447,Vinorelbine-Trastuzumab
C4744767,Eribulin-Trastuzumab
C1541534,Capecitabine-Trastuzumab
C4522185,Paclitaxel-Trastuzumab
C4745315,ABEMAciclib-Fulvestrant
C4744779,ABEMAciclib-Exemestane
C4744780,ABEMAciclib-Anastrozole
C4744778,ABEMAciclib-Letrozole
C4744777,RIBOciclib-Fulvestrant
C4744773,RIBOciclib-Exemestane
C4744772,RIBOciclib-Anastrozole
C4744771,PALBOciclib-Fulvestrant
C4744770,PALBOciclib-Exemestane
C4745317,PALBOciclib-Anastrozole
C4744724,EVERolimus-Fulvestrant
C4745316,EVERolimus-Tamoxifen
C4684873,EVERolimus-Exemestane
C3665472,Chemotherapy NOS
C4526517,Capecitabine-Bevacizumab
C0175210,TAC
C0039411,TC
C0001246,AC
C0950521,CMF
C0042567,Vertebrate
C2987506,Uterus/Cervix
C0042131,Uterus
C0040578,Trachea
C0038351,Stomach
C0038293,Sternum
C0037993,Spleen
C0225317,Soft Tissue
C0021852,Small Bowel
C0178298,Skin
C0036277,Scapula
C0036270,Scalp
C4047398,Sacral Mass
C0035561,Rib
C0035359,Retroperitoneum
C0225778,Pleural Fluid
C0032225,Pleura
C0031050,Pericardium
C0003964,Peritoneal Fluid
C0031153,Peritoneum
C0030797,Pelvis
C0029928,Ovary
C0230060,Orbital Floor
C0028977,Omentum
C0029180,Orbit
C0686905,Not available
C1272460,Not Applicable
C0027530,Neck
C0025066,Mediastinum
C0026845,Muscle
C0240318,Mediastinal Mass
C0024109,Lung
C0024204,Lymph Node
C0022646,Kidney
C0023884,Liver
C0230136,Intercostal space
C0020889,Iliac Bone
C0018787,Heart
C0016976,Gallbladder
C0018246,Groin
C0014852,Esophagus
C0015556,Fallopian Tube
C0015811,Femur
C0228134,Epidural
C0205076,Chest Wall
C0009368,Colon
C0021853,Bowel
C0006497,Buttock
C0007765,Cerebellum
C0007874,Cervix
C0005953,Bone Marrow
C0005682,Bladder
C0238729,Axillary mass
C0004600,Back
C0001625,Adrenal Gland
C0003617,Appendix
C0836916,Abdominal Wall
C1336860,Undifferentiated Malignant Neoplasm
C0221013,Systemic Mastocytosis
C0278701,Stomach Adenocarcinoma
C1336027,Solid Papillary Carcinoma of the Breast
C1261473,Sarcoma NOS
C0279702,Renal Clear Cell Carcinoma
C0149978,Rectal Adenocarcinoma
C0281361,Pancreatic Adenocarcinoma
C0007131,Non-Small Cell Lung Cancer
C0027022,Myeloproliferative Neoplasm
C0026985,Myelodysplasia
C1275874,Metaplastic Squamous Cell Carcinoma
C0025202,Melanoma
C0152013,Lung Adenocarcinoma
C1265996,Large Cell Neuroendocrine Carcinoma
C0019621,Langerhans Cell Histiocytosis
C0853879,Invasive Breast Carcinoma
C0024301,Follicular Lymphoma
C0017636,Glioblastoma Multiforme
C0338106,Colon Adenocarcinoma
C0206698,Cholangiocarcinoma
C0027641,Breast Neoplasm NOS
C0678222,Breast Carcinoma
C0279680,Bladder Urothelial Carcinoma
C0010606,Adenoid Cystic Carcinoma
C0007117,Basal Cell Carcinoma
C0023467,Acute Myeloid Leukemia
C0001418,Adenocarcinoma NOS
C0040128,Thyroid
C0030274,Pancreas
C0034882,Rectum
C0700374,Palate
C0726639,Impact
C0441833,panel
C0332241,Equivocal
C0205160,Negative
C1446409,Positive
C2827736,3+
C2827735,2+
C2827734,1+
C0919414,0
C0205430,Mixed
C0205417,Lobular
C1512083,Ductal
C0041951,Ureter
C0030580,Parotid
C0037925,Spinal Cord
C0036760,Serosa
C0022378,Jejunum
C0929176,Hilum
C0016976,Gall Bladder
C0007103,Endometrium
C0013303,Duodenum
C0007806,Cerebrospinal Fluid (CSF)
C0001575,Adnexa
C0003962,Ascites
C0205177,Active
C1518340,NED
C1327616,Secretory
C0205618,Undifferentiated
C0334023,Metaplastic
C1513712,Mucinous
C0001629,Medullary
C0151747,Tubular
C0333348,Inflammatory
C0279565,Invasive Lobular Carcinoma
C1134719,Invasive Ductal Carcinoma
C1334274,Invasive Carcinoma
C0021440,IV
C4697913,IIIA
C0439070,III
C0020980,IA
C0020985,IB
C0441971,M1
C0445034,M0
C0441961,N3
C0441960,N2
C0441962,N1
C0445085,NX
C1709110,N3c
C1709109,N3b
C1709108,N3a
C0445080,N2b
C0445079,N2a
C3869928,N1mi
C1709107,N1c
C0456908,N1b
C0456906,N1a
C0441959,N0
C0040165,T4
C0475372,T1
C0039711,TX
C0475398,T4d
C0475397,T4c
C0475396,T4b
C0475395,T4a
C0041014,T3
C0475386,T1c
C0475385,T1b
C0475383,T1a
C3846409,T1mic
C0475413,Tis
C0475371,T0
C0445085,Nx
C0039711,Tx
C1272696,Not done
C0193867,ALND
C0796693,SLNB
C0917927,BCS
C0009653,Prophylactic
C0040722,TM
C0687676,Post
C0347985,Peri
C0332152,Pre
C1548958,Sequential
C1302313,Lost to Follow up
C0011065,Dead
C2584946,Alive
C3840603,Spanish surname only
C0034043,Puerto Rican
C1553379,Cuban
C0013014,Dominican Republic
C0007457,White
C0085756,Black or African American
C0043210,Female
C0086582,Male
C0039871,thiotepa
C1268647,Extremely dense
C1512426,Heterogenous
C0338204,Herceptin
C0042150,uterus cervix
C1719852,Ultrasonographic echogenicity
C0741688,BREAST CYST ULTRASOUND
C3845572,Received outside of this facility
C3845572,Received outside of this facility
C3845572,Received outside of this facility
C0013230,Investigational New Drugs
C0013230,Investigational New Drugs
C0013230,Investigational New Drugs
C0013230,Investigational New Drugs
C4068833,Vascularity
C0037088,Clinical findings
C0037088,Clinical findings
C0037088,Clinical findings
C0872338,cancer sites
C0205402,Prominent
C0205081,Moderate
C0439855,Complex
C0231242,Complicated
C0205352,Simple
C1268642,Mammography finding
C0585897,History of peripheral vascular disease procedure
C0085096,Peripheral vascular disease
C0018824,cardiac valvular disease
C0332514,Asymmetry
C1512426,Heterogenous
C2935436,ado-trastuzumab emtansine
C0421292,skin changes
C1268647,Extremely dense
C0205081,Moderate
C1512426,Heterogenous
C1710661,Washout
C2598519,Current age
C0280089,Carcinoid tumor of lung
C0858246,Hypo
C0577559,Mass
C0080194,Strain
C0439742,Scattered
C4684449,On Treatment
C2709088,post treatment
C2709094,pre treatment
C0076836,Toremifene
C4519079,veledimex
C0232970,Postmenopausal
C0205271,Irregular
C2348042,Parallel
C0244404,raloxifen
C0278488,metastatic breast cancer
C1268717,Mammographic breast density
C1269792,Surgical pathology identifier
C1299222,Sample identification number
C0023114,laterality
C4727162,Involved-site Radiation Therapy
C4727162,Involved-site Radiation Therapy
C0880159,Pathology report comments [Interpretation] Narrative
C4086448,Histopathology Result
C4542734,"Screening, diagnostic, film, digital or digital breast tomosynthesis (3d) mammography results documented and reviewed"
C0746406,MASS DENSITY NEOPLASM
C4041401,History of ductal carcinoma in situ of breast
C1881055,Personal History of Coronary Artery Disease
C0028794,occult
C0028794,occult
C0028794,occult
C0028794,occult
C0028794,occult
C1160446,determination of bilateral symmetry
C0034510,race
C1268642,Mammography finding
C0449453,Lesion size
C0449453,Lesion size
C0449453,Lesion size
C2168701,shape of lesion
C2168701,shape of lesion
C2168701,shape of lesion
C1268665,Radiographic lesion margin characteristics
C1268665,Radiographic lesion margin characteristics
C1268665,Radiographic lesion margin characteristics
C0405352,Breast Biopsy
C0023114,laterality
C0023114,laterality
C0023114,laterality
C0023114,laterality
C0015031,ethnicity
C1827571,Depth of lesion
C1827571,Depth of lesion
C3496610,Tobacco smoking status
C1268642,Mammography finding
C2023417,echocardiography: morphologic left ventricular ejection fraction non-estimable
C2199689,echocardiography: diastolic dimension of left ventricle
C3173977,Clinical or research indication for test
C0009488,comorbidities
C0442310,Clockface position
C0442310,Clockface position
C0442310,Clockface position
C0442310,Clockface position
C1549501,"Report date/time, report date/time at filing ancillary (i.e., Lab)"
C1549501,"Report date/time, report date/time at filing ancillary (i.e., Lab)"
C1511314,Breast Imaging Reporting and Data System
C1511314,Breast Imaging Reporting and Data System
C1549501,"Report date/time, report date/time at filing ancillary (i.e., Lab)"
C1549501,"Report date/time, report date/time at filing ancillary (i.e., Lab)"
C0447660,Breast quadrant
C0447660,Breast quadrant
C1510755,Accession Number (identifier)
C1510755,Accession Number (identifier)
C1510755,Accession Number (identifier)
C1827571,Depth of lesion
C0447660,Breast quadrant
C0521941,Antiresorptive Agents
C3248288,"Beta-blocker therapy prescribed or currently being taken (CAD,HF)"
C1510755,Accession Number (identifier)
C1320716,Cardiovascular event
C3248291,Aspirin or clopidogrel prescribed or currently being taken (CAD)
C3248289,"Angiotensin Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) therapy prescribed or currently being taken (CAD, CKD, HF) (DM)"
C0488055,Systolic blood pressure
C3248290,Statin therapy prescribed or currently being taken (CAD)
C2348558,Study Start Date
C1511314,Breast Imaging Reporting and Data System
C0262365,mammogram abnormality
C1292734,Treatment intent
C1549501,"Report date/time, report date/time at filing ancillary (i.e., Lab)"
C4050242,Pathologic Complete Response
C0600558,neoadjuvant therapy
C3642344,Breast Carcinoma by Gene Expression Profile
C0678222,Breast Carcinoma
C1148348,Date of death
C0947611,Comment
C0475752,Tumor status
C2706086,Patient Identification Number or Provider Account Number:Identifier:Point in time:^Patient:Nominal
C0421451,Patient date of birth
C0804642,Date first Dx:Date:Pt:Cancer.XXX:Qn
C0804642,Date first Dx:Date:Pt:Cancer.XXX:Qn
C1266869,Hospital AND/OR institution
C0079399,Gender
C0804762,Date last contact:Time Stamp -- Date and Time:Point in time:^Patient:Quantitative
C1301894,Medical record number
C1299487,Patient name
C1707251,Cancer Other
C0804642,Date first Dx:Date:Pt:Cancer.XXX:Qn
C0449259,Clinical course
C1306459,Primary malignant neoplasm
C0804642,Date first Dx:Date:Pt:Cancer.XXX:Qn
C0449259,Clinical course
C1306459,Primary malignant neoplasm
C0804642,Date first Dx:Date:Pt:Cancer.XXX:Qn
C0449259,Clinical course
C1306459,Primary malignant neoplasm
C0040300,Body tissue
C1146895,Vital status:Type:Point in time:^Patient:Nominal
C1516974,Estrogen Receptor Status - Clinical Trial Eligibility Criteria
C4319467,Cells.estrogen receptor/100 cells:NFr:Pt:Breast cancer specimen:Qn:Immune stain
C3847093,HER2 signals/nucleus:EntNum:Pt:Tiss:Qn:FISH
C4482618,HER2:PrThr:Pt:Breast cancer specimen:Ord:FISH
C1977461,HER2/CEP17:Ratio:Pt:Tiss:Qn:FISH
C4482619,HER2:PrThr:Pt:Breast cancer specimen:Ord:Immune stain
C1512413,HER2/Neu Status
C0947611,Comment
C0024884,"Mastectomy, Radical"
C0807712,Recurrence date
C1715904,Histologic type:Type:Pt:Breast tumor:Nom
C3897311,Tumor Findings Laterality
C1522449,Therapeutic radiology procedure
C1316189,Tumor site:Anat:Pt:Specimen:Nom
C0449259,Clinical course
C1514471,Progesterone Receptor Status
C4482761,Progesterone receptor Ag:PrThr:Pt:Breast cancer specimen:Ord:Immune stain
C1516974,Estrogen Receptor Status - Clinical Trial Eligibility Criteria
C0804708,Site of distant metastasis:Anat:Pt:Cancer.XXX:Nom
C3847093,HER2 signals/nucleus:EntNum:Pt:Tiss:Qn:FISH
C1977461,HER2/CEP17:Ratio:Pt:Tiss:Qn:FISH
C4482619,HER2:PrThr:Pt:Breast cancer specimen:Ord:Immune stain
C1512413,HER2/Neu Status
C1266869,Hospital AND/OR institution
C0947611,Comment
C0807712,Recurrence date
C0804708,Site of distant metastasis:Anat:Pt:Cancer.XXX:Nom
C1514471,Progesterone Receptor Status
C0030231,Palliative Care
C1706721,Adjuvant Radiation Therapy
C3260343,Deprecated TNM clinical staging - distant metastases - M [PhenX]
C3260342,Deprecated TNM clinical staging - nodal involvement - N [PhenX]
C3260340,Deprecated TNM clinical staging [PhenX]
C3260341,Deprecated TNM clinical staging - primary tumor - T [PhenX]
C0804642,Date first Dx:Date:Pt:Cancer.XXX:Qn
C4319467,Cells.estrogen receptor/100 cells:NFr:Pt:Breast cancer specimen:Qn:Immune stain
C1516974,Estrogen Receptor Status - Clinical Trial Eligibility Criteria
C4482618,HER2:PrThr:Pt:Breast cancer specimen:Ord:FISH
C1977461,HER2/CEP17:Ratio:Pt:Tiss:Qn:FISH
C0941291,HER2 Ag:PrThr:Pt:Tiss:Ord:Immune stain
C1512413,HER2/Neu Status
C1266869,Hospital AND/OR institution
C3847093,HER2 signals/nucleus:EntNum:Pt:Tiss:Qn:FISH
C1715913,Histologic grade:Score:Pt:Breast cancer specimen:Ord:Nottingham
C1715904,Histologic type:Type:Pt:Breast tumor:Nom
C4048239,Histology aspects
C3696935,Operative procedure on axilla
C2919643,Surgical procedure on primary malignant neoplasm of breast
C4255413,Date and time of surgery
C1708790,Lymphatic Invasion
C3829127,Menopause Status
C0205292,Multifocal
C0027663,"Neoplasms, Multiple Primary"
C4086646,Number of Lymph Nodes Positive
C1518435,Nuclear Grade
C1709318,Oncotype DX Breast Cancer Assay
C3898101,Oncotype DX DCIS Score
C3260347,Deprecated TNM pathologic staging - distant metastases - M [PhenX]
C3260346,Deprecated TNM pathologic staging - nodal involvement - N [PhenX]
C4319465,Cells.progesterone receptor/100 cells:NFr:Pt:Breast cancer specimen:Qn:Immune stain
C1514471,Progesterone Receptor Status
C0947611,Comment
C3897268,Tumor Results Sequence Number
C3260344,Deprecated TNM pathologic staging [PhenX]
C3260345,Deprecated TNM pathologic staging - primary tumor - T [PhenX]
C3696935,Operative procedure on axilla
C2919643,Surgical procedure on primary malignant neoplasm of breast
C4255413,Date and time of surgery
C3897311,Tumor Findings Laterality
C0804677,Size:Length:Point in time:Tumor:Quantitative
C1656582,Date radiation ended:TmStp:Pt:Cancer.XXX:Qn
C1522449,Therapeutic radiology procedure
C0947611,Comment
C1531783,Date treatment started
C1266869,Hospital AND/OR institution
C2584899,Date of procedure
C4319467,Cells.estrogen receptor/100 cells:NFr:Pt:Breast cancer specimen:Qn:Immune stain
C1516974,Estrogen Receptor Status - Clinical Trial Eligibility Criteria
C1977461,HER2/CEP17:Ratio:Pt:Tiss:Qn:FISH
C4482618,HER2:PrThr:Pt:Breast cancer specimen:Ord:FISH
C4482619,HER2:PrThr:Pt:Breast cancer specimen:Ord:Immune stain
C1512413,HER2/Neu Status
C1266869,Hospital AND/OR institution
C3847093,HER2 signals/nucleus:EntNum:Pt:Tiss:Qn:FISH
C4319371,Body structure included in specimen:Anat:Pt:Specimen:Nom
C4048239,Histology aspects
C1510755,Accession Number (identifier)
C4319465,Cells.progesterone receptor/100 cells:NFr:Pt:Breast cancer specimen:Qn:Immune stain
C1514471,Progesterone Receptor Status
C1510755,Accession Number (identifier)
C0947611,Comment
C1299222,Sample identification number
C1299258,Primary malignant neoplasm of breast
C1316189,Tumor site:Anat:Pt:Specimen:Nom
C0456204,Specimen type
C1268567,Protein-tyrosine kinase inhibitor
C2935436,ado-trastuzumab emtansine
C0728747,trastuzumab
C1511576,Cyclin-Dependent Kinase Inhibitor Agents
C0392920,Chemotherapy Regimen
C3899266,End Date and Time of Procedure
C1880501,Endocrine Drug Therapy
C0021083,Immunotherapy
C1266869,Hospital AND/OR institution
C0677922,Ovarian ablation
C0677922,Ovarian ablation
C1882413,Poly(ADP-ribose) Polymerase Inhibitors
C1273562,Procedure stopped
C3173309,Date treatment or therapy started
C2585119,Experimental therapeutic procedure
C0521982,Response to treatment
C0087111,Therapeutic procedure
C0947611,Comment
C1285155,Procedure by intent
C3897268,Tumor Results Sequence Number
C0804708,Site of distant metastasis:Anat:Pt:Cancer.XXX:Nom
C0804708,Site of distant metastasis:Anat:Pt:Cancer.XXX:Nom
C3897268,Tumor Results Sequence Number
C3897268,Tumor Results Sequence Number
C3897268,Tumor Results Sequence Number
C3898879,Hormone Receptor/HER2 Positive
C0679246,advanced disease
C0586519,Specimen from breast
C4527347,Lapatinib/Capecitabine Regimen
C1541246,Lapatinib/Trastuzumab Regimen
C4527351,Pertuzumab/Trastuzumab/Paclitaxel Regimen
C4527349,Pertuzumab/Trastuzumab/Docetaxel Regimen
C4527348,Pertuzumab/Trastuzumab Regimen
C1134648,Cyclophosphamide/Fluorouracil/Methotrexate/Trastuzumab
C1327926,Exemestane/Trastuzumab
C1134443,Anastrozole/Trastuzumab
C0879507,Docetaxel/Trastuzumab
C0935898,Carboplatin/Docetaxel/Trastuzumab
C0796529,Gemcitabine/Monoclonal Antibody HER2
C0338364,Paclitaxel/Trastuzumab
C1879500,AC-T Regimen
C0248241,CEF regimen
C0935867,Bevacizumab/Vinorelbine
C0054427,cyclophosphamide/doxorubicin/fluorouracil protocol
C1134527,Bevacizumab/Docetaxel
C0392920,Chemotherapy Regimen
C0054554,CAMF protocol
C4087027,GDC-0810
C1541558,everolimus/letrozole
C4086837,sacituzumab govitecan
C4289971,Anti-PD-L1 Monoclonal Antibody
C0199976,Lymphokine activated killer cell therapy
C0879250,HER-2-neu peptide vaccine
C1298653,Patient declined anti-cancer treatment
C1272695,Done (qualifier value)
C1521726,partial response
C1518340,No Evidence of Disease
C1306577,Death (finding)
C1709536,Physician Decision
C0580105,Change of medication
C3896765,Selective Estrogen Receptor Degrader SRN-927
C3827144,CEP-37440
C3827146,CB-839
C3827076,SGN-LIV1A
C1511576,Cyclin-Dependent Kinase Inhibitor Agents
C2585119,Experimental therapeutic procedure
C0085533,"Chemotherapy, Adjuvant"
C0439673,Unknown
C0439673,Unknown
C1762617,Weak
C0332241,Equivocal
C0010606,Adenoid Cystic Carcinoma
C0014537,Structure of epidural space
C1282471,Local recurrence of malignant tumor of breast
C0441766,Stage level 1
C0205160,Negative
C1298196,Nottingham Combined Grade III: 8-9 points
C0281267,bilateral breast cancer
C4018978,Unilateral Breast Neoplasms
KEY_CUI,KEY_CUI_MRCONSO_STR
